Peptides for perimenopause: what the evidence actually supports

What did @laurenlhale actually say?

Lauren describes a multi-pronged approach to perimenopause that includes hormone replacement, supplements, stress reduction, and peptides. She credits peptides specifically with helping "joint pain, gut health, muscle growth, sleep, libido" and even "hair loss, skin, inflammation and weight gain." She's switched from a functional medicine provider to a telehealth compounding platform for cost reasons, and she frames peptides as "one piece of your puzzle that might be missing." To her credit, she explicitly says this is not for everyone. That caveat matters. What she does not say is which peptides she's actually using, which makes fact-checking the specific claims nearly impossible. She mentions using something "for growth hormone, sleep, libido and visceral fat" without naming the compound. That vagueness protects her legally but leaves viewers no real information to evaluate.

Does the science back this up?

Some of it, yes. But the evidence base is thinner than this video implies, and the leap from rodent studies to confident human claims is a wide one.

For growth hormone secretagogues like ipamorelin or CJC-1295, there is legitimate research suggesting they raise IGF-1 levels and may support body composition. A 2019 study by Stanley et al. in the Journal of Clinical Endocrinology and Metabolism found growth hormone-releasing peptides improved lean mass in older adults, though the sample sizes were modest. Sleep effects from ipamorelin are often cited anecdotally but remain poorly characterized in peer-reviewed trials specific to perimenopausal women.

BPC-157, frequently promoted for gut health and joint repair, has a compelling preclinical profile. Sikiric et al. have published extensively on it in Current Pharmaceutical Design. The problem is almost all of that work is in rats. The human evidence is essentially nonexistent by clinical trial standards. Claiming it helps gut health in perimenopause specifically is a significant extrapolation.

GHK-Cu for skin and hair has more human data. A 2015 review by Pickart and Margolina in Rejuvenation Research documented wound healing and collagen-stimulating properties in human tissue studies. Still, controlled trials in perimenopausal populations are sparse.

What did they get wrong (or right)?

She got the framing partially right. Perimenopause does disrupt sleep architecture, body composition, joint comfort, and mood, and there are plausible biological mechanisms by which growth hormone secretagogues could address some of those changes. Declining growth hormone pulsatility is a real phenomenon in midlife women documented by Van Cauter et al. in JAMA as far back as 2000. Addressing it is not a fringe idea.

What she got wrong is scope creep. Listing joint pain, gut health, muscle growth, sleep, libido, hair loss, skin, inflammation, and weight gain as things peptides helped her with implies a single therapeutic class is doing an enormous amount of work. That list conflates compounds with very different mechanisms, safety profiles, and evidence levels. Presenting them as a unified solution is misleading, even if unintentionally so.

She also does not mention that several peptides commonly compounded for these purposes, including BPC-157 and TB-500, are not FDA-approved drugs and are classified by the FDA as bulk substances that may not be compounded under Section 503A or 503B. That is a material regulatory fact her audience deserves to hear.

What should you actually know?

Peptides are not a monolith. The word covers dozens of compounds with entirely different targets, evidence bases, and regulatory statuses. Growth hormone secretagogues have more human data than gut-repair peptides. Copper peptides have more cosmetic evidence than performance peptides. Lumping them together and saying they helped with ten different symptoms obscures more than it reveals.

Compounding pharmacy quality is also a real variable. The FDA has flagged multiple compounding pharmacies for sterility failures and mislabeled concentrations. Saying a platform "compounds peptides safely" is a marketing claim, not a clinical one. Patients should ask for third-party certificates of analysis on any compounded product.

If you are in perimenopause and curious about this category, the most honest answer is: some of these compounds are interesting, the research is early, the regulatory landscape is shifting, and you should be working with a provider who can actually monitor labs, not just approve a subscription. Lauren's instinct to combine approaches, including HRT, stress management, and targeted supplementation, is more defensible than any single compound claim she makes.